Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (May 2020)
36 slides from Prescient Therapeutics's investor presentation, May 26, 2020
Slide 1: Revolutionary CAR-T Platform from University of Pennsylvania
REVOLUTIONARY CAR-T PLATFORM FROM UNIVERSITY OF PENNSYLVANIA OUT IN FRONT OF THE BIGGEST WAVE IN ONCOLOGY 1
Slide 2: Disclaimer
Disclaimer Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current exp
Slide 3: CAR-T has been a paradigm-changing development in cancer treatment
CAR-T has been a paradigm-changing development in cancer treatment… …now we’re about to make it a whole lot better. 3
Slide 4: Presentation Summary
Presentation Summary Transformational technology from UPenn - the global leader in CAR-T Catapults PTX to the forefront of CAR-T development Addressing the biggest problems in the most exciting area of oncology An enabling platform not just for Prescient, but for any other CAR-T player Many developm
Slide 5: What We Do
What We Do Our Personalised Medicine Approaches ASX Listed biotech (ASX: PTX) Developing personalised medicines for cancer • Targeted therapies Targeted CAR-T • CAR-T Therapies Combination Close relationships with world-leading Approaches centres in US and Australia • License from the best in field
Slide 6: Our Goals
Our Goals To develop personalised cancer therapies to improve patient outcomes Focus on unmet or poorly met clinical needs Develop revolutionary technologies to bring the success of CAR-T to more patients Targeted Dramatically increase efficacy and control of CAR-T technology Therapies Drive down th
Slide 7: Emily Whitehead, aged 6
Emily Whitehead, aged 6 Suffering a blood cancer called acute lymphoblastic leukemia. After 16 months of chemotherapy, and two relapses, her leukemia still persisted. Doctors told her parents that Emily would not survive. Emily’s parents, searching for a miracle, enrolled her in a trial at UPenn as
Slide 8: Emily Whitehead today
Emily Whitehead today. “CAR T represents a turning point in the history of human medicine, a genuine revolution in our approach to disease.”1 Response rates of ~80% in certain lymphomas2 Today CAR-T is riding the crest of a second wave of innovation - the goal is a universal CAR-T platform that mass
Slide 9: Firstly, what are T-cells?
Firstly, what are T-cells? T-cells are the soldiers of our immune system They can identify and eradicate foreign invaders, as well as cancer cells Virus-infected cells Cancer cells 9
Slide 10: How do they work?
How do they work? 1 2 3 T-cell receptor can T-cell receptor binds to T-cell activates and recognise surface protein the antigen kills the infected cell (antigen) of infected cell 10
Slide 11: Why can't our T-cells see cancer cells?
Why can’t our T-cells see cancer cells? Cancer has learned to evade our immune system by changing the antigens on its surface Without the right receptor, T-cells cannot identify cancer cells …so how do you reprogram a T-cell to recognise and kill cancer cells? 11
Slide 12: ...by adding a cancer receptor to the T-cell!
...by adding a cancer receptor to the T-cell! CAR-T cell A new receptor that can recognise a cancer antigen is added to a patient’s own T-cells The resultant cell is a “chimera”: the patient’s T-cell + an engineered receptor Chimeric Antigen Receptor T-cell or “CAR-T cell” - can now recognise and ki
Slide 13: How does the CAR-T process work?
How does the CAR-T process work? 1. 2. Blood is collected from the T- Cells are separated and patient removed 3. T-Cells are genetically altered to have special cancer-recognising receptors 5. called Chimeric Antigen Receptor Patient first receives (CAR) Chemotherapy, and then the CAR – T cells are
Slide 14: CAR-T cells are now transformed into cancer killers
CAR-T cells are now transformed into cancer killers Activated CAR-T cell CAR-T cell now has the right receptor kills the cancer cells to recognise and bind cancer cells CAR-T CAR-T cell cell T-cell Expansion & ongoing activity 14
Slide 15: CAR-T therapies approved and in use
CAR-T therapies approved and in use Licensed from UPenn Cost of treatment per patient: Cost of treatment per patient: US$475,000 US$373,000 (A$730,000) (A$574,000) ajmc.com, 2018 15
Slide 16: CAR-T deal activity
CAR-T deal activity Bought for US$11.9B Aug 2017 Bought for Bought for US$9B US$74B Jan 2018 Nov 2019 ajmc.com, 2018 16
Slide 17: CAR-T has had stunning success, but…
CAR-T has had stunning success, but… CAR-T has had spectacular and unprecedented success in treating certain types of blood cancers • ~80% response rates in certain B cell lymphomas The field is now grappling with replicating CAR-T’s success in other cancers However, there are substantial challenges
Slide 18: What is holding back the field of CAR-T?
What is holding back the field of CAR-T? Time and Cost Safety No Control Targets Escape of delivering CAR-T can have Clinicians have no Finding targets that Antigen loss treatment serious safety control of cells post work; leads to relapse concerns infusion Antigen heterogeneity (multiple targets) -
Slide 19: Imagine what could happen to the entire field
Imagine what could happen to the ENTIRE FIELD if even some of these limitations were solved? Imagine if CAR-T could work just as well for other cancers – including solid cancers? 19
Slide 20: Introducing the OmniCAR platform
Introducing the OmniCAR platform Pre-clinical universal, modularised CAR-T platform Potential best-in class universal immune receptor (UIR) Co-inventors Multi-disciplinary technology licensed from UPenn, world renowned for its pioneering and leadership in CAR-T Prescient granted exclusive world-wide
Slide 21: OmniCAR can do what conventional CAR-T cannot
OmniCAR can do what conventional CAR-T cannot Conventional CAR-T OmniCAR Can be given any map; Armed with any weapon Multiple deployments Including several at once • Soldier with only one map • Single weapon Full communication and • Only trained to hit one target control at all times, even • Incapab
Slide 22: How OmniCAR works
How OmniCAR works Unarmed (and inactive) CAR-T cells are administered to patient Targeting Separate administration of targeting ligand ligand results in a complete, armed CAR-T cell On-demand Armed CAR-T cells are activated, resulting tumour lysis in on-demand tumour killing CAR-T cell activity is n
Slide 23: An elegant and effective approach
An elegant and effective approach Innovative SpyCatcher/SpyTag binding system separately licensed from Oxford University Decouples antigen recognition from signalling domains Antigen recognition Switch specificity of the CAR-T cell from one target to another Only universal system with covalent loadi
Slide 24: Overcoming Clinical Limitations of CAR-T
Overcoming Clinical Limitations of CAR-T Universal CAR-T Clinical Challenges Conventional CAR-T (OmniCAR) On-demand activation of CAR-T cell ✓ Controlling CAR-T cell activity post infusion ✓ Control serious side effects (TLS; CRS) ✓ (preventative and responsive) Ability to terminate activity i
Slide 25: Safety: Ability Control Dose & Activity
Safety: Ability Control Dose & Activity Conventional CAR-T OmniCAR • Clinicians have no control over CAR-T activity Clinicians have control post infusion once injected Controlling subsequent dose of binder controls • Balance between safety and efficacy can only CAR-T activity be estimated before inf
Slide 26: Safety: Built-in kill switch
Safety: Built-in kill switch BINDER Conventional CAR-T cells cannot DOSE be switched off – a significant problem if toxicities arise OmniCAR activity can be TOXICITY switched off at-will by ceasing binder administration (or administering a blocking agent) EFFICACY Clinicians can safely reactivate CA
Slide 27: Multi-Antigen Capability with a Single Cell Product
Multi-Antigen Capability with a Single Cell Product Ability to target multiple cancer antigens with a single receptor, single cell product Established proof of principal arming of OmniCAR against several common tumour antigens: • Her2 • EGFR • EpCAM • CD20 Powell, DJ et al, JACS; 2020 27
Slide 28: Ability to Target Multiple Antigens Sequentially
Ability to Target Multiple Antigens Sequentially OmniCAR directed OmniCAR now at cancer antigen 1 directed at cancer antigen 2 Cancer mutates 28
Slide 29: Ability to Target Multiple Antigens Simultaneously
Ability to Target Multiple Antigens Simultaneously OmniCAR directed at multiple cancer antigens Cancers with heterogenous antigens 29
Slide 30: Equal Arming & Equal Tumour Killing
Equal Arming & Equal Tumour Killing Equal arming Specifically directed, at-will killing anti-Her2 anti-EGFR Both anti-EGFR + anti-Her2 CAR-T equally armed with: Only kills cells that the CAR-T is armed against Both anti-EGFR + anti-Her2 anti-EGFR anti-Her2 control OmniCAR CAR-T cells have similar sp
Slide 31: Control: Dose-dependent CAR-T activity!
Control: Dose-dependent CAR-T activity! Ovarian cancer model, targeting with anti-Her2 OmniCAR Loading more binder results in proportionate killing of cancer …and proportionate survival Lasting effects even when cease dosing of binder Powell, DJ et al, JACS; 2020 = dosing window of binder 31
Slide 32: Value of a Universal CAR Platform
Value of a Universal CAR Platform December 2019 Astellas bought Xyphos Biosciences for US$665M (US$120M upfront) Xyphos was in pre-clinical development with their UIR system convertibleCAR OmniCAR has several potential advantages 32
Slide 33: What else can OmniCAR do?
What else can OmniCAR do? Potentially applicable to all Other Applications Improve many cell therapy approaches: cancer types Autologous T-cells (patient’s own cells) Haematological cancers Diagnostics Allogeneic T-cells (off the shelf cells) Solid cancers (a new frontier for Imaging of target tumou
Slide 34: Parallel Development Strategy
Parallel Development Strategy IN HOUSE DEVELOPMENT EXTERNAL DEVELOPMENT Progress lead program Licensing Collaboration Broaden OmniCAR platform Improved versions of 3rd party CAR-Ts using • commercially attractive targets and OmniCAR applications • OmniCAR “Intel Inside®” model Accommodated in curren
Slide 35: Presentation Summary
Presentation Summary ✓ Transformational technology from UPenn - the global leader in CAR-T ✓ Catapults PTX to the forefront of CAR-T development ✓ Addressing the biggest problems in the most exciting area of oncology ✓ An enabling platform not just for Prescient, but for any other CAR-T player ✓ Man
Slide 36: Contact
ASX code: PTX www.ptxtherapeutics.com CONTACT Steven Yatomi-Clarke CEO & Managing Director Prescient Therapeutics Limited steven@ptxtherapeutics.com
Prescient Therapeutics — Investor Presentation (May 2020) on 6ix